The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index, and 1 are not checked yet.
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer
Open accessPublished version of a preprint
Abstract
Abstract High-grade serous ovarian cancer (HGSOC) is often sensitive to initial treatment with platinum and taxane combination chemotherapy, but most patients relapse with chemotherapy-resistant disease. To systematically identify genes modulating chemotherapy response, we performed pooled functional genomic screens in HGSOC cell lines treated with cisplatin, paclitaxel, or cisplatin plus paclitaxel. Genes in the intrinsic pathway of apoptosis were among the top candidate resistance genes in both gain-of-function and loss-of-function screens. In an open reading frame overexpression screen, followed by a mini-pool secondary screen, anti-apoptotic genes including BCL2L1 (BCL-XL) and BCL2L2 (BCL-W) were associated with chemotherapy resistance. In a CRISPR-Cas9 knockout screen, loss of BCL2L1 decreased cell survival whereas loss of proapoptotic genes promoted resistance. To dissect the role of individual anti-apoptotic proteins in HGSOC chemotherapy response, we evaluated overexpression or inhibition of BCL-2, BCL-XL, BCL-W, and MCL1 in HGSOC cell lines. Overexpression of anti-apoptotic proteins decreased apoptosis and modestly increased cell viability upon cisplatin or paclitaxel treatment. Conversely, specific inhibitors of BCL-XL, MCL1, or BCL-XL/BCL-2, but not BCL-2 alone, enhanced cell death when combined with cisplatin or paclitaxel. Anti-apoptotic protein inhibitors also sensitized HGSOC cells to the poly (ADP-ribose) polymerase inhibitor olaparib. These unbiased screens highlight anti-apoptotic proteins as mediators of chemotherapy resistance in HGSOC, and support inhibition of BCL-XL and MCL1, alone or combined with chemotherapy or targeted agents, in treatment of primary and recurrent HGSOC. Implications: Anti-apoptotic proteins modulate drug resistance in ovarian cancer, and inhibitors of BCL-XL or MCL1 promote cell death in combination with chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Results agree with previous CRISPR-Cas9 screens, underscoring the role of apoptotic regulatory genes in modifying sensitivity to cancer therapy.”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 2×
“Kuramochi has a BRCA2 mutation and BRCA1 copy loss, and OVSAHO has BRCA2 copy loss (11, 31); both are deficient in HRR (32).”
BackgroundSelf-citationOptimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 2×
“We performed a genome-scale CRISPR-Cas9 knockout screen with the same HGSOC cell lines and drugs, using a pooled library of 73,687 barcoded sgRNAs targeting 18,454 genes (27).”
BackgroundMethodThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationWhole–genome characterization of chemoresistant ovarian cancer
Patch, A., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P. A., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,572 · cited 3×
“30), Australian Ovarian Cancer Study Group (3), and Cancer Cell Line Encyclopedia (31).”
BackgroundMethodSelf-citationEvaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. D. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,457 · cited 10×
“org Mol Cancer Res; 17(11) November 2019 2287”
BackgroundMethodInfluentialThe MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945 · cited 5×
“Most patients with HGSOC respond to surgery and combination chemotherapy with platinum and taxanes, but >80% eventually develop recurrent disease and chemotherapy resistance, for which few effective therapies exist (1).”
BackgroundInfluentialFrom basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903
Correlating chemical sensitivity and basal gene expression reveals mechanism of action
Rees, M. G., Seashore-Ludlow, B. A., Cheah, J. H., Adams, D., Price, E. V., Gill, S., Javaid, S., Coletti, M. E., Jones, V., Bodycombe, N. E., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1986 · Cited by 883 · cited 2×
“Expression of 18,120 genes was evaluated for correlation with drug response in 658 solid tumor cell lines (39); each point indicates one of the”
MethodSelf-citationSensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W. N., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., et al. (2011) · Nature · doi:10.1038/nature09779 · Cited by 801
Cited by
Sorted by citations
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
Corsello, S. M., Nagari, R. T., Spangler, R. D., Rossen, J., Kocak, M., Bryan, J. G., Humeidi, R., Peck, D., Wu, X., Tang, A. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0018-6 · Cited by 878
Self-citationMechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
“Utilizing siRNA to knockdown Bcl-XL decreases cell survival and resensitizes to chemotherapy [153,229,233].”
BackgroundBeyond matrix stiffness: targeting force-induced cancer drug resistance
Kalli, M., Poskus, M. D., Stylianopoulos, T., & Zervantonakis, I. K. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.006 · Cited by 185
“Additionally, greater expression of antiapoptotic proteins BCL2L1 and MCL1 is associated with worse survival outcomes in patients with ovarian cancer [29].”
BackgroundSelf-citationBCL-w: apoptotic and non-apoptotic role in health and disease
Hartman, M. L., & Czyż, M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2417-0 · Cited by 107
Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
Montero, J., & Haq, R. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1334 · Cited by 75
“Combining several BH3 mimetics, such as MCL1 and BCL2/BCLXL inhibitors, has had significant efficacy in preclinical in vitro and in vivo models (70, 130), leading to their current evaluation in clinical trials (e.”
BackgroundSelf-citationFocus on the molecular mechanisms of cisplatin resistance based on multi-omics approaches
Yue, P., Han, B.-J., & Zhao, Y. (2023) · Molecular Omics · doi:10.1039/d2mo00220e · Cited by 46
Targeting Apoptosis to Overcome Chemotherapy Resistance
Doğan, E., Kara, H. G., Kosova, B., & Çetintaş, V. B. (2021) · Exon Publications eBooks · doi:10.36255/exon-publications.metastasis.chemotherapy-resistance · Cited by 39
“In a chemotherapy-resistant ovarian cancer model, knock-out screening showed that loss of BCL2L1 decreases cell survival whereas loss of pro-apoptotic genes promotes resistance (138).”
BackgroundBcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth
Bodac, A., Mayet, A., Rana, S., Pascual, J., Bowler, A. D., Roh, V., Fournier, N., Craciun, L., Demetter, P., Radtke, F., et al. (2023) · EMBO Molecular Medicine · doi:10.1038/s44321-023-00013-x · Cited by 37
“In cancer, Bcl-xL was linked to tumor cell proliferation and resistance to chemotherapy, including in lung cancer (Stover et al, 2019; Shen et al, 2018).”
Lui, G. Y. L., Shaw, R. C., Schaub, F. X., Stork, I. N., Gurley, K. E., Bridgwater, C., Diaz, R. L., Rosati, R., Swan, H. A., Ince, T. A., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102988 · Cited by 38
“Studies utilising other PARPi have reported synergy between talazoparib and navitoclax [68], or olaparib and navitoclax [69,70], and BCL2L1/2 overexpression mediates ovarian cancer chemotherapy resistance [70], all in the context of HGSC.”
BackgroundStrategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance
Goel, N., Foxall, M. E., Scalise, C. B., Wall, J., & Arend, R. C. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0992 · Cited by 34
An Overview of Candidate Therapeutic Target Genes in Ovarian Cancer
Alexandrova, E., Pecoraro, G., Sellitto, A., Melone, V., Ferravante, C., Rocco, T., Guacci, A., Giurato, G., Nassa, G., Rizzo, F. M., et al. (2020) · Cancers · doi:10.3390/cancers12061470 · Cited by 32
“performed a near genome CRISPR/Cas9 screen in BRCA2 mutant HGSOC cell lines and identified BCL2L1 as a gene that mediates resistance to platinum-based chemotherapy [89].”
BackgroundLet’s make it personal: CRISPR tools in manipulating cell death pathways for cancer treatment
Bayat, M., & Nahand, J. S. (2024) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09907-z · Cited by 28
“This shows the CRISPR screens are also able to identify anti-apoptotic genes as targetable mediators of chemo-resistance (Stover et al. 2019a).”
BackgroundKe, Y., Chen, X., Su, Y., Chen, C., Lei, S., Xia, L., Wei, D., Zhang, H., Dong, C., Liu, X., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.744940 · Cited by 25
“All the 16 proteins have been reported to be implicated in the modulation of drug resistance in OC, namely ABCC1 (48), ABCC2 (49), ABCB1 (50), CD44 (51), ALDH1A1 (52), ABCG2 (53), PROM1 (54), CDKN1A (55), CDH1 (56), EGFR (57), BRCA1 (58), BRCA2 (58), BCL2L1 (59), MDM4 (60), MTOR (61), and BRAF (62); and among the 15 p…”
BackgroundLncRNA GAS8-AS1 Inhibits Ovarian Cancer Progression Through Activating Beclin1-Mediated Autophagy
Fang, Y., Jiang, P., Zhai, H., & Dong, J.-S. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s266389 · Cited by 24
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer
Sarosiek, K. A., & Wood, K. C. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.10.004 · Cited by 23
Self-citationGenome-wide CRISPR/Cas9 screening for drug resistance in tumors
Zhang, Z., Wang, H., Yan, Q., Cui, J., Chen, Y., Ruan, S., Yang, J., Wu, Z., Han, M., Huang, S., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1284610 · Cited by 21
The Identification of New c-FLIP Inhibitors for Restoring Apoptosis in TRAIL-Resistant Cancer Cells
Yaacoub, K., Pedeux, R., Lafite, P., Jarry, U., Aci‐Sèche, S., Bonnet, P., Daniellou, R., & Guillaudeux, T. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46010046 · Cited by 21
“Over the past ten years, evidence has shown that abnormalities in apoptosis signaling pathways, such as the activation of anti-apoptotic proteins, were highly associated with immune and drug resistance [3].”
BackgroundYang, X., Li, Z., Ren, H., Peng, X., & Fu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1018642 · Cited by 20
“Frontiers in Oncology 03 resistance of ovarian cancer cells was positively correlated with Gln catabolism (33).”
BackgroundXiang, C., Chen, L., Zhu, S., Chen, Y., Huang, H., Yang, C., Chi, Y., Wang, Y., Lei, Y., & Cai, X. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07035-4 · Cited by 20
“This prompted us to initially investigate the functions of CRLF1 in ovarian cancer progression.”
Enhancer activation from transposable elements in extrachromosomal DNA
Kraft, K., Murphy, S. E., Jones, M. G., Shi, Q., Bhargava-Shah, A., Luong, C., Hung, K. L., He, B. J., Li, R., Park, S. K., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01788-6 · Cited by 25
“Altogether, the enhancer-associated features and regulatory activity of the luciferase assay suggested that EIE 14, and possibly other EIEs, have been co-opted as regulatory sequences when found on ecDNA, influencing the expression of ecDNA-borne oncogenes.”
Brain Tumors: Development, Drug Resistance, and Sensitization – An Epigenetic Approach
Sarkar, S., Deyoung, T., Ressler, H., & Chandler, W. (2023) · Epigenetics · doi:10.1080/15592294.2023.2237761 · Cited by 18
A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer
Rendo, V., Schubert, M., Khuu, N., Rodríguez, M. F. S. P., Whyte, D., Ling, X., van den Brink, A., Huang, K., Swift, M. L., He, Y. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56301-2 · Cited by 20
Self-citationDual inhibition of FGFR4 and BCL-xL inhibits multi-resistant ovarian cancer with BCL2L1 gain
Guo, T., Gu, C., Li, B., & Xu, C. (2021) · Aging · doi:10.18632/aging.203386 · Cited by 18
“com 19758 AGING BCL-xL inhibitor has been proposed to sensitize platinum in OvCa [24].”
BackgroundRole of non-coding RNAs in modulating the response of cancer cells to paclitaxel treatment
Ghafouri‐Fard, S., Shoorei, H., Abak, A., Raza, S. H. A., Pichler, M., & Taheri, M. N. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111172 · Cited by 15
Adnan Awad, S., Dufva, O., Klievink, J., Karjalainen, E., Ianevski, A., Pietarinen, P., Kim, D., Potdar, S., Wolf, M., Lotfi, K., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101521 · Cited by 14
“35 DSRT profiles of CML-LSPCs demonstrated specific sensitivities to additional functional drug classes, which represent potential combination candidates to synergize with TKIs.”
LINC00152 knockdown suppresses tumorigenesis in non-small cell lung cancer via sponging miR-16-5p
Hu, H., Chen, C., Chen, F., & Sun, N. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-59 · Cited by 14
“miR-126-5p has been considered to regulate the tumorigenesis of ovarian cancer via targeting BCL2L2 (27).”
BackgroundOverview of BH3 mimetics in ovarian cancer
Bufalo, D. D., & Damia, G. L. M. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102771 · Cited by 12
Qin, X., Presser, A. G., Johnson, L., Matoba, Y., Shay, B., Xu, W., Choiniere, J., Fraser, C., Garbicz, F., Spetz, J. K. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.24.661170 · Cited by 11
Self-citationKara, H. G., Doğan, E., Çetintaş, V. B., Aktan, Ç., Çakıroğlu, E., Eroğlu, Z., Jafari, D. A., Korkmaz, K., Şentürk, Ş., & Kosova, B. (2025) · FEBS Journal · doi:10.1111/febs.70099 · Cited by 8
Li, X., Guo, Y., Xing, Z., Gong, T., Yang, L.-J., Yang, T., Chang, B., Wang, X., Yu, B., & Guo, R. (2024) · Oncology Reports · doi:10.3892/or.2024.8781 · Cited by 7
“Targeting Bcl‑2/Bcl‑xL, either using genetic knockdown methods or small molecule inhibitors, enhanced platinum or paclitaxel sensitivity in ovarian cancer cell lines (9) and patient samples (37,38).”
BackgroundMethodTalbot, T., Lu, H., & Aboagye, E. O. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00589-z · Cited by 7
“Several BCL2 family genes scored highly, and BH3-mimetics have therefore been proposed as treatments, particularly in the context of synergising with chemotherapy or re-sensitising resistant cancers to chemotherapy: [49] in vivo combination cytotoxicity studies may help to refine clinical trials for relapsed disease.”
BackgroundTighe, A., Nelson, L., Morgan, R. D., Barnes, B. M., Lin, I., Littler, S., Altringham, J., Tan, J. L., McGrail, J. C., & Taylor, S. S. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102160 · Cited by 3
Frizzled 6 endows high‐grade serous ovarian cancer with stem‐like properties and chemoresistance
Chen, S., Yang, G. Y., Shi, Q., Wan, N., Lin, R., Wang, L., Hu, X., Zhuang, X., Yu, L., & Sui, M. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23789 · Cited by 3
Skipper, T. S., Dickson, K.-A., Denes, C. E., Waller, M. A., D'Araujo, T. Y., Neely, G. G., Bowden, N. A., Faiz, A., & Marsh, D. J. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01102-4 · Cited by 2
“…data and at pres-ent have contributed to multi-omics pipelines, revealed novel ARID1A synthetic lethal partners in OCCC, proposed biomarkers for improving treatment selection criteria, and identified molecular targets likely to be synergistic with standard-of-care chemotherapies [27, 29, 30, 38].”
InfluentialGupta, S., Patni, K., Kaur, S., & Dhanjal, J. K. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07153-3 · Cited by 2
“Furthermore, elevated levels of the antiapoptotic protein BCL2L1 (also present in our dataset) have been associated with poorer survival outcomes in ovarian cancer patients [51], reinforcing its contribution to therapy resistance through apoptosis evasion.”
Zhou, L., Xiang, J., & He, Y. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-15852-9 · Cited by 2
Yan, Z., Jin, Z., Sui, H., Peng, K.-H., & Shi, C. (2022) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-022-00243-z · Cited by 2
Sellitto, S., Caredio, D., Bimbati, M., Mariutti, G., Cerisoli, M., Frick, L. D., Bouris, V., Morales, C. O. O., Vena, D. L., Neupane, S., et al. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014056 · Cited by 2
A compendium of Amplification-Related Gain Of Sensitivity (ARGOS) genes in human cancerPreprint
Rendo, V., Schubert, M., Khuu, N., Rodríguez, M. F. S. P., Huang, K., Swift, M. L., He, Y. J., Zerbib, J., Smith, R., Raaijmakers, J. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.16.571980 · Cited by 2
Self-citationThe emerging role of JAK inhibitors in ovarian cancer: new kids on the block?
Al-Bataineh, R., Sharie, A. H. A., & Altal, O. F. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001591 · Cited by 2
“In addition, OC exhibits overexpression of Bcl-2, an anti-apoptotic gene, which modulates chemo-resistance and negatively in fl uences survival [5] .”
BackgroundPooladanda, V., Xu, R. F., Zarrella, D. T., Matoba, Y., Shimada, C., Kumar, S., Kim, E., DiBenedetto, P. J., Qin, X., Sarosiek, K. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.20.699925 · Cited by 1
Self-citationThe Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers
Bairi, K. E., Jarroudi, O. A., & Afqir, S. (2021) · Springer eBooks · doi:10.1007/978-981-16-1873-4_3
Li, X., Xing, Z., Gong, T., Yang, L.-J., Yang, T., Chang, B., Wang, X., Yu, B., & Guo, R. (2022) · Research Square · doi:10.21203/rs.3.rs-1957169/v1
Recurrent breakpoints in the BRD4 locus reduce toxicity associated with gene amplificationPreprint
Wala, J. A., Dalin, S., Webster, S., Shapira, O., Busanovich, J. P., Beroukhim, R., Bandopadhayay, P., & Rendo, V. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.31.606009
Understanding and tackling the resistance to BH3-mimetics in diffuse large B-Cell lymphoma
Yildirim, N. (2024) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.88346
Recurrent breakpoints in the BRD4 locus reduce toxicity associated with gene amplification
Wala, J. A., Dalin, S., Webster, S., Shapira, O., Busanovich, J. P., Sarmashghi, S., Beroukhim, R., Bandopadhayay, P., & Rendo, V. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.100815
Genomic Strategies for Identification and Validation of Targets in Personalized Medicine
Toscano, C. A., & Medina, E. D. (2026) · Springer handbooks · doi:10.1007/978-3-032-01636-2_17
BCLXL blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer
Venkatachalam, A., Strathman, A. R., Hou, X., Correia, C., Meng, X. W., McGehee, C. D., Balczewski, E. A., Duffield, L. N., Rossman, O. K., Wong, C., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02870-7
Mitochondrial priming in human germ cell tumors is dependent on MCL1 and BCL2L1Preprint
Anniko, S., Khan, S., Morton, J. R., Iftikhar, W., Teixeira, A., Willis, C. R. G., Riches‐Suman, K., Poterlowicz, K., Shnyder, S. D., Mitchell, R. T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.22.752028
“In NCCIT and 2102EP cells, the inhibition of MCL1 alone similarly enhanced the cell death response following DNA damage, an effect similarly observed in TCam-2, GCT-44 and JAR cell lines.”
Metadata
- Authors
- Stover, E. H., Baco, M. B., Cohen, O., Li, Y. Y., Christie, E. L., Bagul, M., Goodale, A., Lee, Y., Pantel, S., Rees, M. G., Wei, G., Presser, A. G., Gelbard, M. K., Zhang, W., Zervantonakis, I. K., Bhola, P. D., Ryan, J., Guerriero, J. L., Montero, J., Liang, F. J., Cherniack, A. D., Piccioni, F., Matulonis, U. A., Bowtell, D. D. L., Sarosiek, K. A., Letai, A., Garraway, L. A., Johannessen, C. M., & Meyerson, M.
- Affiliations
- Broad Institute (US)
- The University of Melbourne (AU)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Eli Lilly (United States) (US)
- Corresponding author
- Meyerson, Matthew
- ORCID
- Stover, Elizabeth H.
- Cohen, Ofir
- Li, Yvonne Y.
- Christie, Elizabeth L.
- Goodale, Amy
- Lee, Yenarae
- Rees, Matthew G.
- Presser, Adam G.
- Gelbard, Maya K.
- Zervantonakis, Ioannis K.
- Bhola, Patrick D.
- Ryan, Jeremy
- Guerriero, Jennifer L.
- Montero, Joan
- Liang, Felice J.
- Cherniack, Andrew D.
- Piccioni, Federica
- Matulonis, Ursula A.
- Bowtell, David D.L.
- Sarosiek, Kristopher A.
- Letai, Anthony
- Garraway, Levi A.
- Johannessen, Cory M.
- Meyerson, Matthew
- Venue
- Molecular Cancer Research
- Published
- 2019-11-01
- Volume
- 17
- Issue
- 11
- Pages
- 2281-2293
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- PMC
- PMC6825578
- OpenAlex
- W2970182852
- Cited by
- 49
- References
- 50
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 10 · 2023: 7 · 2022: 6 · 2021: 6 · 2020: 7
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Victorian Cancer Agency (ECSG15012)
- National Health and Medical Research Council (APP1124309, APP1092856)
- SU2C TVF (D2015-037)
- Ministerio de Economia y Competitividad (RYC-2015-18357)
- Postdoctoral Individual National Research Service (F32CA180733)
- NCI (K99CA222554, 1U54CA224068, 1R01CA219943, 1R35CA197568)
- NHMRC (APP1117044)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- high-grade serous ovarian cancer, chemoresistance, anti-apoptotic genes, Bcl-xL, Bcl-w, Bcl-2, Mcl-1, apoptosis, cisplatin, paclitaxel, Bcl-xL inhibitors, olaparib, CRISPR-Cas9 knockout screen, drug resistance
- MeSH terms
- Antineoplastic Agents, Cisplatin, Female, Humans, Ovarian Neoplasms, Apoptosis, Paclitaxel, Drug Resistance, Neoplasm, Genomics, Cell Line, Tumor, Apoptosis Regulatory Proteins, bcl-X Protein, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
